| gap-pubmed-20260410- | Does the protective role of Trem2/Tyrobp signaling in aortic dissection translat | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which Trem2/Tyrobp signaling inhib | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What mechanisms link dysbiosis-induced BBB permeability changes to specific neur | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do specific microbial metabolites affect CNS cell function during neuroinfla | open | 0.86 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the precise molecular mechanisms by which gut microbiota influences inf | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do cellular interactions within the 100-μm plaque microenvironment coordinat | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms drive the temporal shift from oligodendrocyte dysfunct | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What specific neurotrophic factors mediate the non-myelinating support functions | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does oligodendrocyte pathology initiate neurodegeneration in pre-symptomatic | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which oligodendrocytes provide met | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do natural compounds selectively target diseased versus healthy proteostatic | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which natural compounds modulate p | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the 4 enriched canonical pathways identified by RNA sequencing in the c | resolved | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does the combined FUS-aducanumab treatment activate phagocytic microglia and | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms drive the 8.1-fold increase in aducanumab brain delive | resolved | 0.87 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does TDP-43 overexpression in only a minority of neurons lead to network-wid | resolved | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does NPTX2 overexpression cause neurotoxicity at the cellular and molecular | resolved | 0.86 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What molecular mechanisms drive TDP-43 fragmentation and aggregation in neurons | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines differential therapeutic responses to ApoE-targeted therapies ac | open | 0.79 | 0.00 | 2026-04-10 | 0 | | precision-medicine |
| gap-pubmed-20260410- | How should APOE genotype information be integrated into ATX(N) biomarker framewo | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | precision-medicine |
| gap-pubmed-20260410- | How does APOE genotype mechanistically modulate AD pathophysiology beyond amyloi | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the common vs disease-specific astrocyte-mediated mechanisms driving ne | resolved | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do disease-specific astrocyte phenotypes beyond A1/A2 contribute to distinct | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms determine whether reactive astrocytes adopt neurotoxic | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does dysfunction of palmitoylation/depalmitoylation enzymes lead to neurolog | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific therapeutic targets and strategies for modulating palmitoy | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does altered palmitoylation mechanistically contribute to pathological chara | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why don't CSF and urine LRRK2 levels correlate despite similar total protein con | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What accounts for the sex-specific differences in pS1292-LRRK2 progression patte | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why are pS1292-LRRK2 levels in CSF exosomes saturated and 10-fold higher than ur | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does RAB21 depletion selectively affect SLC2A1 recycling but not IGF2R or WL | open | 0.74 | 0.00 | 2026-04-10 | 0 | | metabolic-regulation |
| gap-pubmed-20260410- | What is the molecular mechanism by which RAB21 regulates fission of retromer-dec | open | 0.77 | 0.00 | 2026-04-10 | 0 | | cellular-trafficking |
| gap-pubmed-20260410- | What determines the conservation of intercellular signaling disruptions between | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does A3AR agonism restore tissue integrity and behavioral function in vascul | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link reduced Serpine2 expression to enhanced OPC diffe | open | 0.84 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does pre-treatment timing matter for empagliflozin's β-catenin-mediated neur | open | 0.76 | 0.00 | 2026-04-10 | 0 | | stroke-medicine |
| gap-pubmed-20260410- | Does empagliflozin's neuroprotective effect require SGLT2 presence in brain endo | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurovascular-biology |
| gap-pubmed-20260410- | How does empagliflozin specifically inhibit β-catenin ubiquitination in cerebral | open | 0.84 | 0.00 | 2026-04-10 | 0 | | cerebrovascular-biology |
| gap-pubmed-20260410- | How do emerging inflammasomes contribute to neurodegeneration and what is their | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which emerging inflammasome sensor | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do peripheral ALP changes reflect or influence central nervous system pathol | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why is optineurin specifically reduced in PD patient PBMCs compared to other ALP | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms cause coordinated dysregulation of ALP proteins in peripheral bl | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines which subpopulation of exosomes receives tau-containing complexe | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does the KFERQ-like motif-LAMP2A-HSP70 complex specifically target tau to ex | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What obstacles prevent EV-based treatments from progressing to clinical trials d | open | 0.76 | 0.00 | 2026-04-10 | 0 | | translational-medicine |
| gap-pubmed-20260410- | What specific mechanisms enable EVs to cross the blood-brain barrier while other | open | 0.80 | 0.00 | 2026-04-10 | 0 | | drug-delivery |
| gap-pubmed-20260410- | What determines the divergent pathological trajectories between lipid metabolism | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neuropathic-pain |
| gap-pubmed-20260410- | How do voltage-gated calcium channels mechanistically link sex-specific patholog | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuropathic-pain |
| gap-pubmed-20260410- | What molecular mechanisms drive the female-specific complement-kininogen axis ac | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |